Your Health, We Care
Release date: 2026-01-26 14:00:02 Recommended: 18
The side effects of lorlatinib involve multiple systems, including the central nervous system, endocrine system, digestive system, respiratory system, neuromusculoskeletal system, cardiovascular system and liver. Patients shall follow the doctor’s advice, closely monitor their conditions and report any abnormalities in a timely manner.
Lorlatinib may induce peripheral neuropathy, leading to cognitive impairment, mood disorders, as well as symptoms such as dizziness, headache and sleep disorders. These symptoms may be associated with the drug’s penetration into the central nervous system. In addition, some patients may experience mild symptoms including dizziness, headache, somnolence and memory decline. Usually, these symptoms will resolve spontaneously within a few weeks of treatment. However, if the symptoms persist or worsen, the doctor must be notified promptly.
During lorlatinib treatment, patients may develop endocrine and metabolic abnormalities such as hypercholesterolemia, hyperglycemia and hyperkalemia, all of which may pose threats to patients’ health. Specifically, lorlatinib may also cause elevations in serum cholesterol or triglycerides. Therefore, regular monitoring of these indicators is required, and the dosage should be adjusted according to the doctor’s recommendations.
Lorlatinib may irritate the gastrointestinal tract, resulting in symptoms like nausea, vomiting and diarrhea, accompanied by a significant elevation in serum lipase. Patients can alleviate these symptoms by adjusting their dietary habits, such as eating small frequent meals, choosing easily digestible foods and avoiding spicy foods.
Given that lorlatinib is primarily indicated for lung cancer treatment, some patients may present with lung-related symptoms including dyspnea, shortness of breath and cough. These symptoms may be linked to drug-induced pulmonary inflammation or infection and must be reported to the doctor promptly for management.
Some patients may experience joint pain, myalgia and back pain after taking lorlatinib, and severe cases may even suffer from limb pain.
Although specific symptoms are not specified in the above context, cardiovascular disorders are also among the potential side effects of lorlatinib. Patients need to stay vigilant and report any abnormalities to the doctor without delay.
Lorlatinib may exert adverse effects on the liver, manifesting as symptoms such as jaundice, abnormal liver function and hepatitis. During the course of treatment, liver function monitoring and regular blood tests may be required.
Patients with Hepatic or Renal Impairment: Dosage adjustment is necessary, and close monitoring is required for the risk of drug accumulation.
Pregnant and Lactating Women: The drug may cause harm to the fetus. Strict contraception should be practiced or breastfeeding should be discontinued.
It should be noted that despite the potential side effects, lorlatinib still demonstrates favorable efficacy in the treatment of lung cancer. Patients must adhere to the doctor’s instructions during administration, pay close attention to their bodily reactions and seek medical attention promptly for any discomfort.
